Evidence‐based consensus on opportunistic infections in inflammatory bowel disease

Evidence‐based consensus on opportunistic infections in inflammatory bowel disease Inflammatory bowel disease (IBD), mainly including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic non‐specific intestinal disease. The chronic, protracted course of IBD severely affects the patient's quality of life. The treatment of IBD has gone through three phases. Glucocorticoids were introduced in the 1950s, while immunosuppressive agents began to be used in the 1960s, and therapeutics is now in the era of biological agents. With the progression and continuous standardization of its treatment, treatment efficacy for IBD has made great progress, resulted in significantly decreased complications and mortality in the patients. However, monotherapy or combination therapy with these drugs will change patient's immune status, which may bring corresponding issues, particularly an increased risk of opportunistic infection.Opportunistic infection refers to micro‐organisms that have limited or no pathogenic capacity in healthy human bodies but cause diseases or induce infections when the immune system is compromised by other diseases such as acquired immunodeficiency syndrome (AIDS) or drug medications such as immunosuppressive agents. IBD patients are at a high risk for opportunistic infections. First, the disease itself can cause a reduced nutritional status in IBD patients. Second, the application of glucocorticoids, immunosuppressive and biological agents can severely inhibit patient's immunity. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Digestive Diseases Wiley

Evidence‐based consensus on opportunistic infections in inflammatory bowel disease

Loading next page...
 
/lp/wiley/evidence-based-consensus-on-opportunistic-infections-in-inflammatory-l1QzfWK4yo
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd
ISSN
1751-2972
eISSN
1751-2980
D.O.I.
10.1111/1751-2980.12578
Publisher site
See Article on Publisher Site

Abstract

Inflammatory bowel disease (IBD), mainly including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic non‐specific intestinal disease. The chronic, protracted course of IBD severely affects the patient's quality of life. The treatment of IBD has gone through three phases. Glucocorticoids were introduced in the 1950s, while immunosuppressive agents began to be used in the 1960s, and therapeutics is now in the era of biological agents. With the progression and continuous standardization of its treatment, treatment efficacy for IBD has made great progress, resulted in significantly decreased complications and mortality in the patients. However, monotherapy or combination therapy with these drugs will change patient's immune status, which may bring corresponding issues, particularly an increased risk of opportunistic infection.Opportunistic infection refers to micro‐organisms that have limited or no pathogenic capacity in healthy human bodies but cause diseases or induce infections when the immune system is compromised by other diseases such as acquired immunodeficiency syndrome (AIDS) or drug medications such as immunosuppressive agents. IBD patients are at a high risk for opportunistic infections. First, the disease itself can cause a reduced nutritional status in IBD patients. Second, the application of glucocorticoids, immunosuppressive and biological agents can severely inhibit patient's immunity.

Journal

Journal of Digestive DiseasesWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial